我国药品创新发展趋势分析与建议
Analysis and suggestions on the development trend of drug innovation in China
-
摘要: 为了充分评估我国在全球药品创新所处阶段，进一步优化我国药品创新环境，释放药品创新活力，本文从全球药品研发创新市场现状、研发投入、产品管线、政策支持以及发展趋势等角度，结合我国药品创新发展的特点，着重比较分析我国药品创新的全球竞争状况，发现我国药品创新存在着创新发展阶段落后于发达国家、扎堆研发竞争、突击式的研发冒进、药品创新过度依赖资本市场等现实问题，针对性提出持续改善中国新药创新环境、理性选择差异化竞争与新赛道、合理制定药品创新发展策略、引导资本回归创新研发本质以及构建药品创新“双循环”战略等建议。Abstract: In order to comprehensivehy evaluate the stage of China in the global drug innovation, to further optimize the environment for drug innovation in China, and to unleash the vitality of drug innovation, this article mainly analyzes through comparison China''s situation of drug innovation in global competition from such perspectives as the current situation of the global drug R&D innovation market, R&D investment, product pipeline, policy support, and development trends, combined with the characteristics of China''s drug innovation development.It can be seen that China''s pharmaceutical innovation is faced with such practical problems as lagging behind some developed countries in terms of innovation development, companies bunching into research and development innovation, sudden research and development rush, and excessive dependence on capital markets for pharmaceutical innovation.Accordingly, this paper puts forward suggestions on continuously improving China''s new drug innovation environment, rationally selecting differentiated competition and new tracks, reasonably formulating drug innovation development strategies, guiding capital to return to innovative research and development, and constructing a "double cycle" strategy for drug innovation.
-
-
[1] Lloyd I.Pharma R&D Annual Review 2020[EB/OL].( 2020-07-18 )[2021-09-12 ].https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2020/files/whitepapers/rd-review-2020-whitepaper-update.pdf .[2] Li R, Meng J, Zhao RC, et al. Analysis of research and development status of new drugs in 2022[J]. Chin Bull Life Sci (生命科学), 2023, 35(1): 80-87. [3] Frost & Sullivan. China CRO Industry Market Research Report.[EB/OL][ 2020-06-19 ].https://www.frostchina.com/content/insight/detail?id=62f366d357d0761f000a3433 .[4] BDO. Revenue, R&D and biotech''s future[EB/OL]. [ 2021-12-20 ].https://www.bdo.com/BDO/media/Misc-Documents/LS_Biotech-Brief-Report_Summer-2021_WEB.pdf .[5] Deloitte. Seeds of change: measuring the return from pharmaceutical innovation 2020[EB/OL]. ( 2021-07-20 )[2021-12-20 ].https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-sciences-health-care /deloitte-uk-measuring-the-return-from-pharmaceutical-innovation-2021.pdf .[6] Chen J, Dong Z. Influence and countermeasures and suggestions of medical outsourcing in China on the basis of drug registration system reform[J]. China Pharm (中国药业), 2018, 27(23): 70-73. [7] Wu X, Shao R. Current situation and analysis of venture capital of innovative medicine[J]. Chin J Pharm (中国医药工业杂志), 2020, 51(8): 1070-1079. [8] Fu P, Lu JJ, Sun SY. Discussion on prospect of pharmaceutical innovation market and development of CRO industry in 2020[J]. Tianjin Sci Technol (天津科技), 2020, 47(5): 94-96. [9] Yao W, Yan JZ, Shao R. A study on the evaluation criteria of medical insurance negotiation admittance for innovative drugs in typical countries and its enlightenment to China[J]. Chin J New Drugs (中国新药杂志), 2021, 30(12): 1057-1062. [10] Yin SQ, Zhang H, Liu YH. The effect of policy implementation and some relevant suggestions on the inclusion of innovative tumor drugs in the national reimbursement drug list[J]. Chin Health Econ (中国卫生经济), 2021, 40(1): 22-24. [11] IQVIA. Global trends in R&D: overview through 2020[EB/OL]. ( 2021-05-19 )[2021-10-02 ].https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d .[12] China Pharmaceutical Innovation and Research Development Association (PhIRDA), R&D-Based Pharmaceutical Association Committee (RDPAC). Promoting simultaneous R&D, registration and review of innovative drugs, fostering pharmaceutical innovation system in China[J]. China Food Drug Administ Magaz (中国食品药品监管), 2022, 7(222): 4-13. [13] Chen H, Chen PX. The hidden worries of "assault R&D"[J].Bus Manage (企业管理), 2020, 5: 48-53. [14] Sun TY. China''s pharmaceutical innovation has entered the second tier globally[J].China Econ Week (中国经济周刊), 2022, 5: 62-64. -
期刊类型引用(10)
1. 刘仲仪. 创新药产业发展：经济属性、关键挑战与推进路径. 福建师范大学学报(哲学社会科学版). 2025(03): 60-68+169 . 
百度学术
2. 于飞，卢静，高辰旭，李敬伟. 中外创新药物医保支付的比较研究. 医药导报. 2024(03): 470-476 . 百度学术
3. 刘亚琴，张梦晓，初绽，杨心督. 着力优化创新政策环境 助力医药产业高质量发展——我国药品研发创新态势分析及思考. 价格理论与实践. 2024(05): 82-86+222 . 百度学术
4. 周增娜，徐莉莉，盛威午. 我院药学部中西药物管理的现状与优化策略. 中医药管理杂志. 2024(13): 84-86 . 百度学术
5. 陈功，罗艳，叶连宝. 以培养创新药物研究人才为目标的药物化学教学改革. 药学教育. 2024(05): 43-46 . 百度学术
6. 高松. 中美创新药产业格局对比分析及对拉动中国经济增长的启示. 广东经济. 2024(19): 66-71 . 百度学术
7. 党子悦，张钰，谈维，郭冬梅. 2015年至2023年我国审评上市药品分析. 中国药业. 2024(23): 6-11 . 百度学术
8. 吕倩鹏，吴红，刘智勇. 政策工具视角下我国创新药物研发政策量化研究. 中国卫生事业管理. 2024(12): 1393-1399 . 百度学术
9. 刘曙霞，王琰，杨爽，王雅晴，胥美美. 中国创新药物研发现状与发展建议（英文）. Chinese Medical Sciences Journal. 2024(04): 288-297 . 百度学术
10. 高慧. 新质生产力驱动下西部城市生物医药产业发展研究——以昆明市为例. 云南科技管理. 2024(06): 40-43 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 152
- HTML全文浏览量: 158
- PDF下载量: 377
- 被引次数: 10
下载:
